Portfolio Update

THE THROGMORTON TRUST PLC All information is at 30 November 2012 and unaudited. Performance at month end is calculated on a cum income basis One Three One Three Month Months Year Years Net asset value 0.1% 6.3% 19.5% 74.1% Share price 0.0% 6.2% 15.6% 79.2% Numis plus AIM (ex Inv Cos) 0.2% 5.7% 16.5% 39.3% Sources: BlackRock and Datastream At month end Net asset value capital only: 235.10p Net asset value incl. income: 238.00p Share price: 193.25p Discount to cum income NAV 18.8% Net yield: 1.6%* Total assets: £174.4m** Gross market exposure^: 104.8% Ordinary shares in issue: 73,130,326*** *Calculated using current year interim and prior year final dividends paid. **Includes current year revenue and excludes the gross exposure through contracts for difference. ***Excluding 7,400,000 shares held in treasury. ^Long positions plus short positions as a percentage of net asset value. Ten Largest Sector Weightings % of total assets Support Services 10.1 Software & Computer Services 7.9 Oil & Gas Producers 6.8 Financial Services 6.3 General Retailers 6.2 Electronic & Electrical Equipment 6.2 Chemicals 5.9 Travel & Leisure 5.5 Pharmaceuticals & Biotechnology 5.0 Media 5.0 ---- Total 64.9 ==== Market Exposure (Quarterly) 29.02.12 31.05.12 31.08.12 30.11.12 Long 119.8% 119.1% 116.1% 115.6% Short 13.0% 12.8% 12.3% 10.8% Gross exposure 132.8% 131.9% 128.4% 126.4% Net exposure 106.8% 106.3% 103.8% 104.8% Ten Largest Equity Investments (in alphabetical order) Company Ashtead Aveva AZ Electronic Materials Bellway Booker Howden Joinery Oxford Instruments Senior Victrex Workspace Commenting on the markets, Mike Prentis and Richard Plackett, representing the Investment Manager noted: During November the Company's NAV per share rose by 0.1% on a cum income basis whilst the benchmark index rose by 0.2%. The FTSE 100 Index increased by 1.9% (on a total return basis). Sector allocation in the long only portfolio was slightly positive with our overweight position in speciality chemicals companies contributing to relative performance. Stock selection was marginally negative. The CFD portfolio contributed well with gains being achieved on both the long and the short CFDs during the month. We see this as quite significant and an indication that in fairly flat markets the fundamental assessment we make of companies can help to achieve profits on our gross risk position, not just on our net CFD position. No stock contributed more than 0.25% to relative performance in the long only portfolio, positively or negatively. Our largest contributor to negative stock selection in the month was from a smaller holding, Brainjuicer. Brainjuicer warned profits would be below expectations because large corporate customers had delayed spending on market research tools late in the year. Interestingly sales of Brainjuicer's most innovative tools were up 39% in the 10 months to 31 October 2012 compared to the prior period, but other research tools revenues were down 22% over the same period. The company has net cash and a strong management team. We expect a better performance next year and therefore we are retaining our holding. We had good results, trading updates or meetings from/with various holdings during the month including Oxford Instruments, Keller, Aveva, Hyder Consulting, Big Yellow and Workspace. There were no new holdings during the month. We continued to sell a number of small holdings where we see limited near term upside. 14 December 2012 ENDS Latest information is available by typing www.blackrock.co.uk/thrg on the internet, "BLRKINDEX" on Reuters, "BLRK" on Bloomberg or "8800" on Topic 3 (ICV terminal). Neither the contents of the Manager's website nor the contents of any website accessible from hyperlinks on the Manager's website (or any other website) is incorporated into, or forms part of, this announcement.
UK 100

Latest directors dealings